Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Kymera Therapeutics (NASDAQ: KYMR) will participate in multiple investor fireside chats in November 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) will participate in multiple investor fireside chats in November 2025. Events and times: Guggenheim Healthcare Innovation in Boston on Nov 10, 9:00 AM ET; UBS 2025 Global Healthcare in Palm Beach on Nov 10, 11:45 AM ET; Stifel 2025 Healthcare in New York on Nov 11, 1:20 PM ET; TD Cowen Virtual Immunology & Inflammation Summit on Nov 13, 10:30 AM ET; and Jefferies Global Healthcare in London on Nov 19, 11:00 AM GMT.
Live webcasts and replay archives will be available under News and Events in the Investors section of the company's website at www.kymeratx.com.
Details
News Market Reaction – KYMR
On Nov 3, the day this news came out, KYMR closed 3.43% below the previous close.
Data tracked by StockTitan Argus for the Nov 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
- Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA on November 10 at 9:00 a.m. ET;
- UBS 2025 Global Healthcare Conference in Palm Beach, FL on November 10 at 11:45 a.m. ET;
- Stifel 2025 Healthcare Conference in New York, NY on November 11 at 1:20 p.m. ET;
- TD Cowen Virtual Immunology & Inflammation Summit on November 13 at 10:30 a.m. ET; and
- Jefferies Global Healthcare Conference in London, UK on November 19 at 11:00 a.m. GMT.
Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.